Beta Bionics今日对外宣布，其革命性产品Mint™贴片泵已正式获得美国食品药品监督管理局（FDA）的批准。这标志着该公司在糖尿病管理设备领域迈出了关键性的一步。与此同时，公司还揭开了下一代胰岛素给药算法——3D Intelligence™的神秘面纱。
Mint™贴片泵的获批，无疑为胰岛素依赖型患者带来了全新的治疗选择。这款设备的设计理念，旨在打破传统胰岛素泵的束缚，以更轻巧、更智能的形态，满足现代患者对便捷性与精准度的双重需求。
而3D Intelligence™算法的发布，则进一步彰显了Beta Bionics在数字化医疗创新上的雄心。该算法有望通过更智能的剂量计算，帮助患者实现更平稳的血糖控制。这两项进展的叠加，或将在糖尿病护理领域引发新一轮的技术变革。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.